Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
3(12%)
Results Posted
0%(0 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_2
9
36%
Ph phase_1
16
64%

Phase Distribution

16

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
16(64.0%)
Phase 2Efficacy & side effects
9(36.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

3

trials recruiting

Total Trials

25

all time

Status Distribution
Active(4)
Completed(15)
Terminated(2)
Other(4)

Detailed Status

Completed15
unknown4
Active, not recruiting3
Withdrawn1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
3
Success Rate
93.8%
Most Advanced
Phase 2

Trials by Phase

Phase 116 (64.0%)
Phase 29 (36.0%)

Trials by Status

active_not_recruiting312%
unknown416%
completed1560%
withdrawn14%
not_yet_recruiting14%
terminated14%

Recent Activity

3 active trials
Showing 5 of 25
active_not_recruitingphase_2

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT05167721
active_not_recruitingphase_1

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

NCT02315027
active_not_recruitingphase_1

Impact of Mesenchymal Stem Cells in Knee Osteoarthritis

NCT03477942
not_yet_recruitingphase_1

Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism

NCT06858254
completedphase_1

Mesenchymal Stem Cells for Multiple Sclerosis

NCT01730547
View all 25 trials

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT05167721Phase 2

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

Active Not Recruiting
NCT02315027Phase 1

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

Active Not Recruiting
NCT03477942Phase 1

Impact of Mesenchymal Stem Cells in Knee Osteoarthritis

Active Not Recruiting
NCT06858254Phase 1

Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism

Not Yet Recruiting
NCT01730547Phase 1

Mesenchymal Stem Cells for Multiple Sclerosis

Completed
NCT03778333Phase 1

Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden

Completed
NCT02497443Phase 1

Safety of Autologous MSC Infusion to Treat Epilepsy

Completed
NCT04432467Phase 1

Fertility Restoration Using Autologous Mesenchymal Stem Cells

Completed
NCT04146519Phase 2

Parkinson's Disease Therapy Using Cell Technology

Unknown
NCT02981576Phase 1

Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.

Completed
NCT01609283Phase 1

A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis

Completed
NCT03333681Phase 1

Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients

Completed
NCT02249676Phase 2

Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders

Completed
NCT02460770Phase 1

Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device

Withdrawn
NCT00875654Phase 2

Intravenous Stem Cells After Ischemic Stroke

Completed
NCT01895439Phase 1

Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis

Completed
NCT02945462Phase 1

Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)

Completed
NCT01157650Phase 1

Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue

Completed
NCT02064062Phase 2

Autologous Stem Cells in Achilles Tendinopathy

Unknown
NCT02118519Phase 2

Mesenchymal Stem Cells in Knee Cartilage Injuries

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
25